NASDAQ$SKIN
SkinHealth Systems Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Net sales decreased slightly year-over-year, but were driven by growth across international markets.
BeautyHealth reported Q4 2023 financial results with net sales of $96.8 million, a decrease of (1.3)% compared to the prior year period. The results reflect lower equipment sales in the Americas, substantially offset by steady growth in Americas consumables net sales and strong device placement in Asia-Pacific.
- Net sales were $96.8 million, a decrease of (1.3)% compared to the prior year period, with challenges in the Americas largely offset by growth in APAC and EMEA.
- Gross margin was 47.2% compared to 67.8% in the prior year. Adjusted gross margin was 54.6% compared to 73.6% in the prior year, impacted by higher inventory related charges and higher product and warranty costs.
- Net loss was $(9.4) million compared to net income of $6.5 million in the prior year, primarily due to gross margin pressures.
- Adjusted EBITDA was $3.4 million compared to $17.6 million in the prior year, primarily due to gross margin pressures.
Headline financials
Revenue & EPS history
Beauty Health · Revenue · Quarterly
$96.8M
Revenue by segment
Beauty Health · $97.4M total across 2 segments · Q3 2023
- Delivery Systems$51M+3.9%52.4%
- Consumables$46.4M+16.9%47.6%
Forward guidance
The company provided financial guidance for the first quarter and full year 2024.
Tailwinds
- First quarter financial guidance reflects our seasonally lowest sales quarter of the year and investments in sales and marketing spend in the quarter.
- Assumes no material deterioration in general market conditions or other unforeseen circumstances beyond the Company's control, such as foreign currency exchange rates.
- Excludes any unannounced acquisitions, dispositions or financings.
- Fiscal Year 2024 Net sales Flat to low-single digit % growth
- Fiscal Year 2024 Adjusted EBITDA > $40 million
Headwinds
- First Quarter 2024 Net sales $77 – $83 million
- First Quarter 2024 Adjusted EBITDA ($6) – ($9) million
- First quarter financial guidance reflects our seasonally lowest sales quarter of the year
- Investments in sales and marketing spend in the quarter
- Assumes no material deterioration in general market conditions or other unforeseen circumstances beyond the Company's control, such as foreign currency exchange rates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.9%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+52.1%
Q1 2025
Best reaction
-61.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -29.9% | -34.9% | |
| Q4 2025 | +19.8% | +11.3% | -15.3% | |
| Q3 2025 | +8.7% | +3.1% | +13.2% | |
| Q1 2025 | +52.1% | +19.4% | +29.0% | |
| Q4 2024 | -5.6% | -9.9% | -26.1% | |
| Q3 2024 | +5.1% | -13.1% | -14.2% | |
| Q2 2024 | -10.4% | +0.8% | +12.8% | |
| Q1 2024 | -20.1% | -18.4% | -39.9% | |
| Q4 2023 | +16.8% | -0.8% | +4.4% | |
| Q3 2023 | -61.4% | -37.2% | -14.7% | |
| Q2 2023 | -6.0% | -12.9% | -24.2% | |
| Q1 2023 | -2.8% | -0.2% | -20.8% | |
| Q4 2022 | +8.7% | +13.5% | +7.4% | |
| Q3 2022 | -25.3% | -12.3% | -4.1% | |
| Q2 2022 | -8.3% | -8.8% | -18.5% | |
| Q1 2022 | -5.4% | +6.6% | +8.9% | |
| Q4 2019 | +4.0% | -4.1% | -12.9% | |
| Q4 2021 | +23.4% | +43.1% | +27.6% | |
| Q3 2021 | -11.9% | -8.0% | -13.9% | |
| Q2 2020 | +8.2% | +7.4% | +26.8% | |
| Q2 2021 | +10.6% | +23.9% | +30.3% | |
| Q1 2021 | +12.8% | +15.9% | +44.7% | |
| Q4 2020 | +2.8% | -0.9% | -10.0% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro